Radioimmunoassay market forecast to hit $1.49 billion by 2035

Market Research Future projects the global radioimmunoassay market will grow from $0.84 billion in 2025 to $1.49 billion by 2035, driven by cancer testing demand, lab automation and expanding diagnostic infrastructure. The forecast points to the strongest gains in Asia-Pacific, while reagents and kits remain the largest product segment.

Why it matters: - The radioimmunoassay market sits at the center of ultra-sensitive testing for cancer, endocrine and other chronic disease applications. - Market Research Future projects the market will expand from $0.84 billion in 2025 to $1.49 billion by 2035. - The forecast implies steady demand for testing platforms, reagents and automated laboratory systems across hospitals, diagnostic labs and research users.

What happened: - Market Research Future said the global radioimmunoassay market will reach $0.89 billion in 2026, the first year of the forecast period. - The firm projects a 5.9% CAGR from 2026 to 2035. - The company linked the forecast to rising cancer and chronic disease prevalence, analyzer automation and public investment in diagnostic infrastructure. - The report includes a free sample.

The details: - Cancer cases worldwide are projected to rise from 20 million in 2024 to more than 35 million annually by 2050, according to WHO projections cited in the report. - Radioimmunoassay remains important for tumor marker detection and endocrine profiling, especially for low-level targets such as thyroglobulin, PSA and CA-125. - New analyzer platforms now use robotic sample loading, barcode tracking and cloud-based quality control dashboards. - Those automation features are said to reduce technician hands-on time by up to 40% and manual error rates by about 35%. - Reagents and kits are the largest product category, with a 62% share in 2025. - Analyzers are the fastest-growing product category, with a projected 6.4% CAGR. - Clinical diagnostics is the largest application segment, generating $0.53 billion in 2025. - Research is the fastest-growing application segment, with a projected 6.7% CAGR. - Hospitals are the largest end-user segment, with a 36% share in 2025. - Clinical diagnostic laboratories are the fastest-growing end-user channel, with a projected 6.2% CAGR. - North America led the market in 2025 with 38% of global revenue, or about $0.32 billion. - Europe held about 28% of the global market in 2025. - Asia-Pacific is the fastest-growing region, with a projected 7.2% CAGR. - South America reached $0.06 billion in 2025. - The Middle East and Africa region is forecast to grow at 6.1% CAGR. - The report highlights detailed market insights.

Between the lines: - The forecast suggests this is still a mature but durable market, with growth driven more by recurring consumables and replacement cycles than by disruptive technology shifts. - Automated analyzers appear to strengthen closed-system purchasing, since one instrument placement can lock in years of reagent demand. - Stricter bioanalytical rules in the FDA, EMA and EU IVDR frameworks are favoring validated commercial assay kits over in-house alternatives. - Emerging-market lab buildouts in India and China are widening the customer base beyond tertiary care centers. - The competitive field remains concentrated, with Siemens Healthineers, DiaSorin and Beckman Coulter among the leading vendors named in the report.

What's next: - Market Research Future expects future growth opportunities in point-of-care gamma-counter systems, companion diagnostics, multiplex panels and AI-driven quality control. - The report also points to expansion opportunities in affordable kits for emerging markets and in ultra-low-activity reagent formulations that reduce radioactive waste. - Continued automation upgrades and diagnostic infrastructure spending should shape purchasing decisions through 2035.

The bottom line: - Radioimmunoassay is projected to keep growing because hospitals and labs still need highly sensitive testing, and they are increasingly willing to pay for automated platforms that support recurring reagent sales.